Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2022-02-15 00:00:00 ET · period of report 2022-02-11 · accession 0001714899-22-000041 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-15 | 2022-02-11 | DNLI | Krognes Steve E. | CFO, Treas | S - Sale | $34.69 | -2,560 | 120.2K | -2% | -$88.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-11 | S | D | 2,560 | $34.69 | 120,221 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $34.50 to $35.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 87,322 restricted stock units. |